DSM-Firmenich stock faces November 4 update after H1 growth

Published on 11/02/2026 at 09:20 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

DSM-Firmenich stock enters a key week before the November 4 trading update. Management has retained its full-year growth outlook as the portfolio shifts.

Portfolio reshaping meets growth test

DSM-Firmenich is moving toward a consumer-focused portfolio after agreeing to sell Animal Nutrition & Health to CVC.
First-half 2026 continuing-operations sales rose 5% like for like, while management kept its full-year outlook.
The November 4 trading update will provide the next operating checkpoint for growth, margins and cash generation.

DSM-Firmenich, CH1216478797, Illustration mit AI erstellt.

DSM-Firmenich is approaching its third-quarter 2026 trading update with growth momentum in its continuing businesses and a portfolio reshaped around consumer ingredients. The company is scheduled to release the update on Wednesday, November 4, according to the Kurums analysis.

The real-time quote of DSM-Firmenich stock was 107.30 euros on Lang & Schwarz at 09:15 CET on Monday, November 2, 2026.

Growth holds as portfolio changes

Continuing-operations sales reached 4.664 billion euros in the first half of 2026, up 5% like for like. Second-quarter growth accelerated to 6%, while Adjusted EBITDA rose 7% like for like to 900 million euros. Currency effects weighed on reported performance, leaving the margin at 19.3%, compared with 19.5% a year earlier.

Perfumery & Beauty led the operating portfolio with 7% like-for-like growth in the first half. Taste, Texture & Health and Health, Nutrition & Care each delivered 4% growth, according to the Kurums review. Core adjusted earnings per share increased 14% to 1.84 euros, helped by a lower share count.

Animal nutrition exit remains central

The planned sale of Animal Nutrition & Health to CVC Capital Partners is intended to leave DSM-Firmenich focused on Perfumery & Beauty, Taste, Texture & Health, and Health, Nutrition & Care. The transaction carries an enterprise value of about 2.2 billion euros, while DSM-Firmenich plans to retain a 20% stake in each of two planned standalone companies.

Closing is expected around the end of 2026, subject to regulatory approvals and employee consultations. The separation follows the sale of the group's Feed Enzyme Alliance stake to Novonesis in 2025 and is designed to reduce exposure to the cyclical economics of animal nutrition.

Guidance sets the next test

Management retained its 2026 outlook for like-for-like growth of 2% to 4%, with performance expected toward the upper end of the range. The group also targets an Adjusted EBITDA margin of around 20% and adjusted gross operating free cash flow of 11% to 12% of sales.

The November 4 update will therefore give investors a fresh view of demand across the continuing businesses, the effect of currency movements and progress toward the margin and cash targets. It will also offer an operating check on the strategy to build a more focused consumer-ingredients group.

European equities remain in focus as the AEX provides the broader Dutch-market backdrop for investors.

For further company developments, see More news and analyses on DSM-Firmenich stock.